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Abstract
Introduction: High mobility group box 1 (HMGB1) is a key mediator of inflammation that is actively secreted by
macrophages and/or passively released from damaged cells. The proinflammatory role of HMGB1 has been
demonstrated in both animal models and humans, since the severity of inflammatory response is strictly related to
serum HMGB1 levels in patients suffering from traumatic insult, including operative trauma. This study was
undertaken to investigate HMGB1 production kinetics in patients undergoing major elective surgery and to address
how circulating mononuclear cells are implicated in this setting. Moreover, we explored the possible relationship
between HMGB1 and the proinflammatory cytokine interleukin-6 (IL-6).
Methods: Forty-seven subjects, American Society of Anesthesiologists physical status I and II, scheduled for major
abdominal procedures, were enrolled. After intravenous medication with midazolam (0.025 mg/Kg), all patients
received a standard general anesthesia protocol, by thiopentone sodium (5 mg/Kg) and fentanyl (1.4 μg/Kg), plus
injected Vecuronium (0.08 mg/Kg). Venous peripheral blood was drawn from patients at three different times, t0:
before surgery, t1: immediately after surgical procedure; t2: at 24 hours following intervention. Monocytes were
purified by incubation with anti-CD14-coated microbeads, followed by sorting with a magnetic device. Cellular
localization of HMGB1 was investigated by flow cytometry assay; HMGB1 release in the serum by Western blot.
Serum samples were tested for IL-6 levels by ELISA. A one-way repeated-measures analysis ANOVA was performed
to assess differences in HMGB1 concentration over time, in monocytes and serum.
Results: We show that: a) cellular expression of HMGB1 in monocytes at t1 was significantly higher as compared to
t0;b )a tt 2, a significant increase of HMGB1 levels was found in the sera of patients. Such an increase was
concomitant to a significant down-regulation of cellular HMGB1, suggesting that the release of HMGB1 might
partially derive from mononuclear cells; c) treatment of monocytes with HMGB1 induced in vitro the release of IL-6;
d) at t2, high amounts of circulating IL-6 were detected as compared to t0.
Conclusions: This study demonstrates for the first time that surgical/anesthesia trauma is able to induce an early
intracellular upregulation of HMGB1 in monocytes of surgical patients, suggesting that HMGB1 derives, at least
partially, from monocytes.
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Up to the present the stress response to an injury such as
surgical/anesthesia trauma has represented a complex,
poorly understood phenomenon. Nevertheless, there is a
growing body of research on this important aspect of the
field. Surgical/anesthesia trauma-induced stress response
is mediated by a massive neuro-endocrine-hormonal flux,
resulting in activation of intracellular signaling pathways
and production of several molecules among which cyto-
kines play a crucial role in regulating the function of acti-
vated cells and in preserving body homeostasis [1,2]. The
intensity of such an inflammatory response is dependent
on many factors, including the magnitude of tissue
damage, the patient’s pre-existing diseases, the type of
surgery and surgeon’s experience, as well as the anesthe-
sia regimen [3,4].
In particular, anesthetic agents are suspected of
impairing the perioperative inflammatory process by
affecting the host cell-mediated immune balance both
directly and indirectly [5]. For example, several in vitro
and in vivo investigations demonstrated the direct
immunosuppressive effect of volatile and non-volatile
anesthetics on various lymphocyte cell lines. Moreover,
drugs employed for inducing and maintaining general
anesthesia, such as opioids and muscle relaxants, as well
as sevoflurane, exhibited a pro-apoptotic effect on lym-
phocyte cells by decreasing mitochondrial transmem-
brane potential or activating extrinsic cell death
pathways [5,6].
Recently, an endocrine family of biomolecules, termed
“alarmins” by J. Oppenhaim and co-workers, is receiving
growing attention as innate danger signals. High Mobi-
lity Group Box 1 (HMGB1) is a 30 KDa protein that
shows all the typical features of alarmins. HMGB1 plays
a pivotal role in inducing and enhancing immune cell
functions as well as in tissue injury and repair [7,8].
In particular, HMGB1 was first described as a DNA-
binding non-histone chromosomal protein that has been
implicated in diverse cellular functions, such as stabiliza-
tion of nucleosomal structure and regulation of tran-
scription factors [9,10].
Later, several research groups showed that HMGB1
exhibits an extracellular role as a cytokine, being actively
secreted by peripheral blood mononuclear cells (PBMCs).
In particular, recent studies have shown a delayed release
of HMGB1 by activated monocytes via a non-classical
vesicle-mediated secretory pathway [11]. Functionally,
HMGB1 is involved in various inflammatory processes
that culminate in the release of cytokines and other
inflammatory mediators [12-15]. Perhaps most of these
effects are initiated by the binding of HMGB1 to the
receptor for advanced glycation end products (RAGE), a
multi-ligand receptor of the immunoglobulin superfamily.
In addition to RAGE, members of the Toll-like receptor
(TLR) family, such as Toll-like receptor 2 and 4 have been
demonstrated to participate in the HMGB1 signaling path-
way [16-18].
It has also been demonstrated that HMGB1 is released
in the serum of subjects undergoing traumatic/surgical
injury [19,20]. However, neither the kinetics of this
event nor how the cellular compartment is involved in
this process is actually known.
Therefore, the aim of this study was to measure
HMGB1 levels in circulating monocytes as well as in the
serum of patients undergoing elective surgical trauma.
In addition, we evaluated a possible relationship between
HMGB1 and Interleukin-6 (IL-6) production, since IL-6
is a key cytokine involved in surgical stress response.
Materials and methods
Patients
Following approval by the Human Subjects Review
Committee and the Research Ethics Board, 47 adult sub-
jects, American Society of Anesthesiologists (ASA) phy-
sical status I and II, scheduled for major abdominal
procedures, were included in a prospective study.
Patients with diabetes, cardiac, pulmonary, renal, vascu-
lar, immunologic, neurodegenerative, infectious or hepa-
tic diseases were excluded from the study.
Subjects who were taking medication known to inter-
fere with hormonal, metabolic or immunological func-
tion as well as pregnant or breast feeding women were
also excluded.
Written informed consent was obtained from eligible
patients during the screening period, at which time phy-
sical examination and medical history were evaluated.
Postoperative complications were recorded throughout
seven post-surgery days. Fifteen control subjects
matched for sex, age and weight were also enrolled.
Informed consent was obtained from the control sub-
jects as well as the patients.
Anesthesia technique
After intravenous medication with midazolam (0.025
mg/Kg), all patients received a standard general anesthe-
sia protocol. Anesthesia induction was performed by
thiopentone sodium (5 mg/Kg) and fentanyl (1.4 μg/Kg).
Vecuronium (0.08 mg/Kg) was injected to facilitate oro-
tracheal intubation during direct laryngoscopy.
Anesthesia was maintained with 60% air in oxygen
supplemented with 1 to 2.5% inspired concentration of
sevoflurane, fentanyl and vecuronium administered
according to clinical need. In all patients a radial artery
catheter was inserted for continuous monitoring of
arterial blood pressure.
In addition, standard parameters such as electrocar-
diogram (ECG), oxygen saturation (SaO2), End-Tidal
carbon dioxide (ETCO2) and hemoglobin (HB) were
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mechanically ventilated by means of S/5 AVANCE
device (Datex-Ohmeda, Helsinki, Finland) with the goal
of achieving an ETCO2 level of 38 to 40 mmHg. Normal
saline and Ringer Lactate solutions were administered
with the infusion rate being adjusted from 6 to 10 ml/
Kg/h according to blood loss. Rectal temperature was
maintained at 37°C by warming fluids before administra-
tion and using an upper bodyB a i rH u g g e r( A r i z a n t
Healthcare Inc., Eden Prairie, MN, USA). Duration of
both surgery and anesthesia was recorded. The same
surgical team performed all operative procedures.
After surgery neuromuscular blockade was antago-
nized with 0.5 to 1.5 mg atropine and 1 to 2.5 mg
intrastigmine. Post-operative pain relief was provided by
intravenous morphine bolus administered (0.20 mg/Kg)
30 minutes before the anticipated end of surgery and
continued by means of elastomeric pump containing
morphine 0.3 mg/Kg throughout 24 postoperative hours.
Samples
Venous peripheral blood was drawn from patients at
three different times, that is, t0: before anesthesia and
surgery, t1: immediately after surgical procedure; and t2:
at 24 hours following intervention. After allowing the
blood to coagulate, the serum was isolated by low-speed
centrifugation at 4°C, frozen and stored at -80°C until
used. In parallel, human peripheral blood mononuclear
cells were isolated from fresh heparinized blood by
Lymphoprep (Nycomed AS Pharma Diagnostic Division,
Oslo, Norway) density-gradient centrifugation and
washed three times in phosphate buffered saline (PBS),
pH 7.4.
Isolation of monocytes
Human peripheral blood mononuclear cells were
washed three times in PBS, pH 7.4. CD14+ monocytes
were purified by incubation with anti-CD14-coated
microbeads (Miltenyi Biotec, Bergisch Gladbach, Ger-
many), followed by sorting with a magnetic device
(MiniMacs Separation Unit; Miltenyi Biotec), according
to the manufacturer’s instructions [21].
Flow cytometric analysis of HMGB1 expression
Cellular localization of HMGB1 was investigated by indir-
ect immunofluorescence assay. Monocytes cells were col-
lected, washed in PBS and then fixed with 2%
paraformaldehyde (PFA) for 20 minutes at room tempera-
ture. The cellular suspension was then washed with cold
PBS and permeabilized with 60 μM digitonin (Calbiochem,
San Diego, CA, USA) in the presence of polyclonal rabbit
anti-human HMGB1 (1 μg/ml, Abcam) for one hour at
room temperature. After washing with cold PBS, cells
were incubated with Fluorescein isothiocyanate (FITC)-
conjugated goat anti-rabbit IgG (Sigma Chem Co, St
Louis, MO, USA) in the presence of 60 μM digitonin for
30 minutes at room temperature.
The unbound Ab was removed by the addition of PBS
containing 0.1% bovine serum albumin (BSA) and centri-
fugation at 5,000 g for three minutes (twice). Nonspecific
binding was determined by an unlabeled isotypic control
antibody (Coulter-Immunotech, Hamburg, Germany).
Cells were analyzed by flow cytometry by an Epics
XL-MCL Cytometer (Coulter Electronics, Hialeah, FL,
USA) equipped with a 488 nm argon-ion laser. For each
histogram, 10,000 cells were counted. Antibody reactiv-
ity was reported as mean fluorescence intensity. The
purity of the monocyte population was checked by
staining with FITC-conjugated monoclonal antibody
(MoAb) anti-CD14 (Sigma Chem Co).
Blood samples collected from 15 healthy volunteers
were analysed as controls.
Preparation of cytosolic and nuclear extracts
Monocyte cells were resuspended in buffer A (20 mM
H E P E S ,p H7 . 9 ,2 0m MK C l ,3 . 0m MM g C l 2,0 . 3m M
Na3VO4, and freshly added 200 μM leupeptin, 10 mM
E64, 300 μMP M S F ,0 . 5μg/ml pepstatin, 5 mM DTT,
0.1% Nonidet P-40) and vortexed. After 30 minutes on
ice, cells were centrifuged for 30 minutes at 10.000 × g
at 4°C. The pellet was resuspended in buffer A + 0.1%
Nonidet P-40 and vortexed. After centrifugation at
10,000 g for five minutes at 4°C, supernatants were
taken as cytosolic extracts and frozen.
Pellets were resuspended in buffer B (40 mM HEPES,
pH 7.9, 0.84 M NaCl, 0.4 mM EDTA, 50% glycerol, 0.3
mM Na3VO4, and freshly added 200 μM leupeptin, 10
μM E64, 300 μMP M S F ,0 . 5μg/ml pepstatin, 5 mM
DTT), and vortexed. After one hour on ice, nuclear
extracts were cleared at 10,000 × g for one hour at 4°C
and supernatants were transferred to new vials. Protein
content was determined by Bradford assay using BSA as
a standard (Bio-Rad Lab., Richmond, CA, USA) and
samples were frozen at -80°C.
Equal amounts of nuclear or cytosolic extracts were
separated in 15% SDS-PAGE under unreducing condi-
tions. The proteins were electrophoretically transferred
onto nitrocellulose membrane (Bio-Rad Lab.) and then,
after blocking with PBS, containing 1% albumin, probed
with monoclonal anti-HMGB1. Bound antibody visua-
lized with HRP-conjugated anti-mouse IgG (Sigma
Chem Co) and immunoreactivity was assessed by the
chemiluminescence reaction, using the ECL Western
blotting system (Amersham Pharmacia Biotech, Buckin-
ghamshire, UK). As a control for purity mouse anti-a-
tubulin monoclonal antibodies (Sigma Chem Co) and
goat anti-laminin B polyclonal antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) were used.
Manganelli et al. Critical Care 2010, 14:R197
http://ccforum.com/content/14/6/R197
Page 3 of 10Immunoblotting analysis
Total protein concentration of serum and plasma sam-
ples was evaluated using the Bradford assay. Equal
amounts of diluted serum samples were then subjected
to sodium-dodecyl sulphate polyacrilamide gel electro-
phoresis (SDS-PAGE). The proteins were electrophoreti-
cally transferred onto polyvinilidene difluoride (PVDF)
membranes (Bio-Rad, Hercules, CA, USA). Membranes
were subsequently blocked with 5% defatted dried milk
in Tris buffered saline (TBS) containing 0.05% Tween-
20 and probed with anti-HMGB1 monoclonal antibody
(Abcam, Cambridge, MA, USA). Bound antibodies were
visualized with HRP-conjugated anti-mouse IgG (Sigma
Chem Co) and immunoreactivity assessed by chemilu-
minescence reaction usingt h eE C LW e s t e r nb l o c k i n g
detection system (Amersham). Densitometric scanning
analysis was performed on Mac OS 9.0 version, using
NIH Image 1.62 software, developed at the U.S. National
Institutes of Health [22].
We measured HMGB1 in both serum and plasma and
the results were virtually the same in all the samples
under test (data not shown).
IL-6 assay
Serum samples were tested for IL-6 levels by enzyme-
linked immunosorbent assay( E L I S A ) ,u s i n gac o m m e r -
cially available ELISA kit (R&D Systems, Inc., Minneapolis,
MN, USA), according to the manufacturer’si n s t r u c t i o n .
Preliminary experiments were designed to determine the
d e t e c t i o nl i m i t sa sw e l la st h el i n e a r i t ya n dr a n g eo ft h e
ELISAs, essentially in accordance with the International
Conference on Harmonisation Q2A and Q2B guidelines
(Committee for Proprietary Medicinal Products, European
Medicines Evaluation Agency). The intra-assay variation
ranged from 3% to 6% and the inter-assay variation from
4% to 9%. The limits of detection were 0.7 pg/ml. In paral-
lel experiments, monocytes, isolated as above from the
patients under test, were incubated in the presence or in
the absence of 100 ng/ml recombinant histidine-tagged
HMGB1 (Sigma Chem Co), 100 ng/ml lipopolysaccharide
(LPS) (Sigma Chem Co) or 100 ng/ml LPS plus 100 ng/ml
HMGB1 for 24 h at 37°C. IL-6 levels in the supernatant
were detected by ELISA as reported above.
Statistical analysis
Summary statistics are presented as mean and Standard
deviation (SD). A one-way repeated-measures analysis
ANOVA was performed to assess differences in
HMGB1 concentration over time, in both monocytes
and serum.
Bonferroni post tests were used to determine the sig-
nificant differences between group means in an
ANOVA setting. Differences were considered statisti-
cally significant when p was less than 0.05.
Results
Patients
Characteristics of patient group as well as type of surgical
procedures are given in Table 1. Anesthesia/operation
time and the average dosage of anesthesia drugs are
reported in Table 2. None of the patients received blood
transfusions during the study time as the components of
transfused blood may have immunomodulatory effects in
the recipient with the potential to increase or suppress
production of HMGB1. Patients did not exhibit any ser-
ious post-operative complications throughout the overall
study period.
Cellular HMGB1 expression
We first analysed HMGB1 expression level in mono-
cytes by flow cytometry. Monocyte population was iden-
tified and gated by CD14 staining. The patients showed
higher basal levels of HMGB1 than healthy donors
(Figure 1a, b), consequent to the underlying diseases of
the patients, but this difference was not statistically sig-
nificant (P > 0.05). Time-course analysis revealed an
increase in the mean fluorescence intensity of HMGB1
in monocytes of the patients at t1 (Figure 1a). Statistical
analysis with all the subjects under test shows that
HMGB1 staining at t1 is significantly higher as com-
pared to t0 (P < 0.0001) or t2 (P < 0.0001) (Figure 1b).
This finding demonstrates that HMGB1 overexpression
in monocytes is an early event in surgical/anesthesia
trauma.
Table 1 Patient population profile and operative
procedures
No. Patients 47
Male 26
Female 21
* Age, yr 64 ± 12
* Weight (Kg) 71 ± 17
ASA (I/II) 15/32
Surgical procedures
Emicolectomy 18
Isterectomy 13
Gastrectomy 9
Hepatic resection 7
*Data are expressed as mean ± standard deviation.
Table 2 Surgery/Anesthesia duration and total anesthesia
drug doses
Surgery/Anesthesia duration (minutes) 174 ± 23/186 ± 17
Anesthesia drugs
Tiopenthal (mg) 359 ± 18
Fentanyl (mg) 0.3 ± 0.09
Vecuronium (mg) 11 ± 4
*Data are expressed as mean ± standard deviation.
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Page 4 of 10Figure 1 Analysis of HMGB1 cellular expression. (a) Flow cytometric analysis of HMGB1 expression in monocytes from one patient and one
control subject (healthy donor). Mononuclear cells were drawn from the patients at three different times, that is, t0: before surgery, t1:
immediately after surgical procedure; t2: at 24 hours following intervention. Cells were stained with polyclonal anti-human HMGB1 1 μg/ml
(Abcam) for one hour at room temperature. Nonspecific binding was determined by an unlabeled isotypic control antibody (Coulter-
Immunotech, Hamburg, Germany). After washing with cold PBS, cells were incubated with FITC-conjugated anti-rabbit IgG and then analyzed by
flow cytometry. Antibody reactivity was reported as mean fluorescence intensity. Histograms show the log fluorescence versus the cell number.
(b) Results of flow cytometric analysis of HMGB1 expression in monocytes from controls (healthy donors) and from the patients under test at
three different times: t0 = before surgery, t1 = immediately after surgical procedure; t2 = at 24 hours following intervention. Mean fluorescence
intensities were measured and plotted values represent mean ± SD. ***t1 vs t0,t 1 vs t2: P < 0.0001. (c) Monocytes cells were sampled at the
indicated time points and subjected to nuclear (N) and cytoplasmic (C) fractionation. The levels of endogenous HMGB1 in the nuclear and
cytoplasmic fractions were determined by immunoblotting with anti-HMGB1 antibodies. Laminin B served as nuclear contamination marker and
a-tubulin as cytoplasmic contamination marker. Protein loading within each compartment was also normalized with Laminin B and a-tubulin,
respectively.
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observed in monocytes may be derived by the nucleus,
both cytosolic and nuclear extracts from monocytes of
all the patients were probed with anti-HMGB1 Ab by
Western blot. The results showed that an increased
expression of HMGB1 in the cytoplasm was observed at
T1 (Figure 1c). Since it was accompanied by a corre-
sponding decrease of HMGB1 expression in the nucleus,
our results suggest that neo-expression of HMGB1 in
the cytoplasm may result from a translocation from the
nucleus.
Serum HMGB1 concentration
In parallel analyses, we detected HMGB1 levels in sera
of patients at the same time points, using Western Blot
(Figure 2a). Densitometric analysis (Figure 2b) revealed
that HMGB1 concentration significantly increases at 24
hours (t2)( P < 0.001) (Figure 2c). On the other hand,
levels of HMGB1 in serum were not significantly
affected immediately after surgical procedure (t1)( P >
0.5), as compared with samples collected before surgery
(t0). These findings provide direct evidence that overex-
pression of HMGB1 by monocytes precedes the increase
of serum HMGB1 concentration in patients.
Serum IL-6 concentration
IL-6 is commonly produced at local tissue sites and then
released into circulation. Perturbation of tissue homeos-
tasis causes IL-6 release in almost all situations and
such a key cytokine is involved in surgical stress
response as well. We, therefore, preliminary analyzed
whether treatment of monocytes with HMGB1 induced
in vitro release of IL-6. Monocytes from the patients
under test were incubated in the presence or in the
absence of HMGB1, LPS or LPS plus HMGB1. The ana-
lysis revealed that all the treatments induced a signifi-
cant increase of IL-6 (P < 0.001) (Figure 3a),
demonstrating that HMGB1 is able to trigger in vitro
release of IL-6 by monocytes. As expected, the levels of
IL-6 following LPS treatment were lower as compared
to those following LPS plus HMGB1 treatment, support-
ing the view of a synergic action between LPS and
HMGB1 [23].
Then, we tested IL-6 levels in serum samples by
ELISA. The results show that this proinflammatory cyto-
kine markedly increases at t2 if compared to t0 and t1
time points (t2 vs t0, P =0 . 0 0 6 ;t 2 vs t1, P =0 . 0 0 3 )( F i g -
ure 3b), indicating that IL-6 release is temporally related
with the observed increase in HMGB1 concentration in
the sera of patients.
Discussion
This study was undertaken to investigate HMGB1 pro-
duction kinetics in patients undergoing major elective
surgery and to address how circulating mononuclear
cells are implicated in this setting. Measurement of
serum level of IL-6 allowed us to study the eventual
relationship between HMGB1 and IL-6, a widely known
marker of surgical stress being directly correlated with
the severity of surgery and the extent of traumatic injury
[20,24]. The results obtained in this work showed that:
a) cellular expression of HMGB1 in monocytes immedi-
ately after the end of surgical procedure was signifi-
cantly higher as compared to preoperative values; b) at
24 hours following surgery, a significant increase of
HMGB1 levels was found in the sera of patients, (inter-
estingly, such an increase was concomitant to a signifi-
cant down-regulation of cellular HMGB1, suggesting
that the release of HMGB1 might, at least partially,
derive from mononuclear blood cells); and c) at the
same time, high amounts of the circulating proinflam-
matory cytokine IL-6 were detected as compared to
baseline preoperative levels.
These current data are consistent with previous obser-
vations demonstrating that HMGB1 is secreted by acti-
vated monocytes and is passively released by damaged
cells following different types of injury, including surgi-
cal/anesthesia stress [19,20,25,26]. It is conceivable that
an increase of HMGB1 in patient sera may also depend
on passive protein release from damaged cells by surgi-
cal procedures as well as from intestinal manipulation
leading to endotoxin translocation which in turn could
induce HMGB1 release [27].
Furthermore, our findings support the view that
increased levels of HMGB1 constitute an early phenom-
enon in traumatic insult, in contrast to the evidence
reported for human sepsis as well as for experimental
models of endotoxemia, in which HMGB1 is considered
a late mediator [28-30]. In particular, the present study
shows for the first time the intracellular overexpression
of HMGB1 in monocytes of patients immediately after
surgery. This finding suggests that surgical stimuli may
rapidly activate intracellular pathways leading to secre-
tion of HMGB1, which is subsequently spilled out into
the circulatory stream. In fact, at 24 hours following
surgery, we observed a down-modulation of cellular
HMGB1in mononuclear blood cells and a significant
increase of HMGB1 levels in serum. It is conceivable
that an increase of HMGB1 in patient sera may also
depend on a passive release of such a protein from
damaged cells following surgical procedures [8]. Never-
theless, following surgical injury, monocytes display an
abnormal intracellular expression of HMGB1 and this
could represent an early event in surgical injury-induced
stress response. The ultimate mechanism underlying
regulation of this active HMGB1 release by surgical sti-
muli as well as the position that surgery per se or gen-
eral anesthesia occupies in the phenomenon, still
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tive Oxygen Species (ROS) were able to induce active
HMGB1 secretion from monocytes in culture and
hypoxic conditions or oxidative stress also trigger hepa-
tocytes to produce HMGB1 through a calcium mediated
cell signaling [31,32].
It is noteworthy that in previous works we demon-
strated both overproduction of ROS by PBMCs in
patients undergoing surgery and general anesthesia and
the capacity of some anesthetic compounds to induce
oxidative stress by altering the mitochondrial redox
state [33,34]. Based on these findings, we hypothesize
Figure 2 HMGB1 serum concentration. (a) Western blot analysis of serum HMGB1 concentration. Serum samples, obtained from the patients
at three different times: t0 = before surgery, t1 = immediately after surgical procedure; t2 = at 24 hours following intervention, were analyzed by
Western blot for reactivity with anti-human HMGB1 MoAb (1 μg/ml). A representative patient is shown together with a control serum from a
healthy donor. (b) Densitometric analysis of serum HMGB1 concentration was revealed by Western blot at three different times: t0 = before
surgery, t1 = immediately after surgical procedure; t2 = at 24 hours following intervention (arbitrary units). (c) Values of densitometric analyses of
all the patients under test are shown as mean ± SD (arbitrary units). ***t2 vs t0,t 2 vs t1: P < 0.001. t1 vs t0: NSS.
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related to the impact of surgery and anesthesia on
redox metabolism and subsequent increased ROS
production.
Moreover, although it is known that apoptotic cells
are not capable of HMGB1 release, since they retain
such a molecule within their nuclear compartment it
was recently demonstrated that macrophages engulfing
apoptotic cells are induced to secrete HMGB1 [12].
Indeed, there is evidence that an accelerated rate of
apoptosis in circulating lymphocytes occurred in the
early postoperative period [35-37]. Thus, we can further
hypothesize that the accelerated rate of apoptosis
following surgery/anesthesia trauma, could be implicated
in the massive HMGB1 release found in patients within
24 hours after a surgical procedure.
Together with an increase of circulating HMGB1, an
additional finding of our study was the demonstration
that: a) treatment of monocytes with HMGB1 induced
in vitro release of IL-6; b) at t2, high amounts of circu-
lating IL-6 were detected as compared to t0.T h i s
strongly suggests that HMGB1 postoperative increase
m i g h tb ea b l et oi n d u c eI L - 6s e c r e t i o n .I th a sp r o v i d e d
evidence that HMGB1 binds Toll-like receptor 4 (TLR-
4) on monocytes surface, thus triggering a signal trans-
duction cascade. TLR pathway activation involves the
Figure 3 Analysis of IL-6 levels. (a) Analysis of IL-6 levels in the supernatants of monocytes from the patients under test. Monocytes were
incubated in the presence or in the absence of 100 ng/ml HMGB1 or 100 ng/ml LPS plus 100 ng/ml HMGB1 for 24 h at 37°C. The samples were
collected and analyzed using a commercially available enzyme-linked immunosorbent assay kit. Values are plotted as mean ± SD. ***HMGB1 vs
control: P < 0.001; LPS vs control: P < 0.001; LPS plus HMGB1 vs control: P < 0.001. (b) Analysis of IL-6 levels in serum samples from the patients
at three different times: t0 = before surgery, t1 = immediately after surgical procedure; t2 = at 24 hours following intervention. Sera from healthy
subjects served as controls. The samples were collected and analyzed using a commercially available enzyme-linked immunosorbent assay kit.
Values are plotted as mean ± SD. **t2 vs t0 : P = 0.006, t2 vs t1: P = 0.003. t1 vs t0: NSS.
Manganelli et al. Critical Care 2010, 14:R197
http://ccforum.com/content/14/6/R197
Page 8 of 10phosphorylation of myeloid differentiation factor 88
(MyD-88) and interleukin-1 receptor-associated kinase
(IRAK), which in turn promotes activation and nuclear
translocation of nuclear factor kB (NF-kB) ultimately
leading to the release of cytokines, including IL-6 [17].
In line with our results, M.J. Cohen et al. found a
positive correlation between IL-6 and HMGB1 levels in
severely injured patients [25].
Further evidence of the potential induction of IL-6
secretion by HMGB1 comes from the studies demon-
strating that HMGB1 significantly correlates with IL-6
in cerebrospinal fluid of humans. Moreover, it has been
shown that intracerebroventricular administration of
HMGB1 enhances brain IL-6 production in animal
models [29,38].
Conclusions
In conclusion, this study demonstrates for the first time
that surgical/anesthesia trauma is able to induce an
early intracellular upregulation of HMGB1 in monocytes
of surgical patients. A statistically relevant increase in
both IL-6 and HMGB1 serum levels at 24 h after sur-
gery fosters the hypothesis that serum post-operative
HMGB1 derives, at least partially, from monocytes and
exhibits the potential to trigger IL-6 secretion. The clini-
cal impact of these findings as well as the ultimate
mechanism by which surgical/anesthesia stimuli modu-
late HMGB1 production, opens an interesting debate
deserving of further studies.
Key messages
￿ Surgical/anesthesia trauma can induce an early
intracellular upregulation of HMGB1 in monocytes
of surgical patients.
￿ HMGB1 is released in the serum of subjects
undergoing traumatic/surgical injury 24 hours later.
￿ A role is suggested for released HMGB1 as a trig-
ger for IL-6 secretion.
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